300142 沃森生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,718,808-19.73%2,821,4414,113,7725,086,4453,462,831
减:营业总成本1,488,300-15.25%2,531,7743,152,2133,806,2232,627,638
    其中:营业成本486,52710.42%572,993597,556609,469394,339
               财务费用(61,836)105.78%(57,024)(70,993)(62,981)(38,721)
               资产减值损失(122,376)24.61%(174,205)(162,640)(61,466)(11,845)
公允价值变动收益91,800-197.98%(98,339)(234,750)(199,335)(280,737)
投资收益2,784-43.16%5,0267,11411,79757,876
    其中:对联营企业和合营企业的投资收益(661)-983.24%130382(1,074)(932)
营业利润140,354-50.94%96,674613,9661,099,440710,275
利润总额136,279-63.54%184,502598,9761,070,465708,945
减:所得税费用32,76641.55%10,10487,651132,239107,593
净利润103,513-70.48%174,398511,325938,226601,352
减:非控股权益(59,930)-163.56%32,23791,935209,574173,604
股东净利润163,443-36.24%142,160419,390728,652427,748

市场价值指针
每股收益 (元) *0.102-36.24%0.0890.2620.4550.273
每股派息 (元) *0.030--0.0100.0100.0100.027
每股净资产 (元) *6.0540.98%5.8965.8175.6525.298
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容